NextCure, Inc. (NXTC) Stock: A Strong Pick In The Biotech Sector?


NextCure, Inc. (NXTC) is headed down in the market today. The stock, one that is focused on the biotechnology industry, is currently trading at $22.77 after falling -6.68% so far today. In terms of biotech stocks, there are several aspects that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories surrounding NXTC:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-08-19 06:02AM What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock?
Jul-18-19 11:20AM 2 Small-Cap Biotech IPOs You Should Know About
Jun-10-19 04:05PM NextCure Reports First Quarter 2019 Financial Results
May-08-19 08:46PM NextCure Announces Pricing of Initial Public Offering of Common Stock
May-04-19 05:25PM IPO Outlook For The Week: Uber (And 11 Others)

Nonetheless, when making an investing decision, prospective investors should look into far more than just news, this is especially the case in the speculative biotech space. Here’s what’s happing when it comes to NextCure, Inc..

Recent Moves From NXTC

Although a move down on a single session, like the fall that we’re seeing from NextCure, Inc. may cause fear in some investors, that by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is generally smart to dig into trends beyond a single trading day. When it comes to NXTC, below are the movements that investors have seen:

  • Past 5 Sessions – Over the past week, NXTC has produced a price change in the amount of 2.34%.
  • Monthly – The monthly ROI from NextCure, Inc. comes to 36.76%.
  • Past Quarter – Over the last three months, the company has produced a return on investment that comes to 14.42%
  • Bi-Annually – Over the past six months, we’ve seen a change that amounts to 0 from the company.
  • Year To Date – Since the close of last year NXTC has resulted in a ROI of 14.42%.
  • Annually – Finally, in the last full year, we’ve seen a change amounting to 0 out of NXTC. Over this period of time, the stock has traded at a high of -11.37% and a low of 64.29%.

Rations That Traders Should Look Into

Looking at various ratios associated with a stock generally gives traders a look of how risky and/or potentially profitable a pick might be. Below are some of the important ratios to look at when looking at NXTC.

Short Ratio – The short ratio is a measure of short interest. As the ratio heads up, it shows that more investors have a belief that the value of the stock is headed for declines. Throughout the sector, biotech stocks tend to carry a higher short ratio. However, we also see quite a few short squeezes in the space. Nonetheless, as it relates to NextCure, Inc., the stock’s short ratio comes to 0.95.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure If a company is able to pay for its debts when they come due with only quick assets or current assets. In the biotech industry, several companies are reliant on continued investor support, the current and quick ratios can look bad. Nonetheless, quite a few gems in the biotech sector come with great current and quick ratios. As it relates to NXTC, the quick and current ratios work out to 12.80 and 12.80 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the share price. In this case, the book to share value ratio works out to -38.21.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotechnology space, this is an important ratio to look into. In this case, the cash to share value is 5.48.

Analyst Opinions Of NextCure, Inc.

Although it’s not a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a good idea to consider their thoughts in order to validate your own opinions before making an investment decision in the biotechnology sector. Here are the recent moves that we have seen from analysts with regard to NXTC.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-09-19 Initiated BofA/Merrill Buy $25
Jun-03-19 Initiated Piper Jaffray Overweight $26
Jun-03-19 Initiated Morgan Stanley Overweight $25

Is Big Money Interested in NextCure, Inc.?

One thing that I have come to understand in my brief period on Earth has been that good investors tend to follow the moves made by big money. So, investors that are looking to keep their investments relatively safe will watch investments made by institutions and insiders. So, is big money flowing in regard to NXTC? Here’s the scoop:

Institutions own 31.10% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 3.50% percent of NXTC shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 22.92M shares of NextCure, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, NXTC has a float of 20.15M.

I also like to follow the short percent. Think about it, when a high percentage of the float available for trading is shorted, the overall feeling in the market is that the company is going to lose value. As far as it relates to NXTC, the percentage of the float that is sold short is 0.49%. Most investors would say that a high short percent of the float is any percentage over 40%. However, I’ve seen that anything over 26% is probably going to be a a play that could prove to be very risky.

What We’ve Seen In Financial Results

What have ween seen from NXTC in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – Currently, Wall St. analysts have expectations that NXTC will generate earnings per diluted share in the amount of -2.91, with -0.47 to be announced in the earnings report for the current quarter. Although this data is not based on earnings, because we are chatting on the topic of analysts, NXTC is presently rated a 1.70 when rated on a scale from 1 to 5 where 1 is the worst average Wall St. analyst rating and 5 is the best rating.
  • 5-Year Sales – Over the past 5 years, NextCure, Inc. has created a movement in sales volume that works out to be 0. Earnings per diluted share over the period have generated a change of 0.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings performance, or Q/Q data as it is commonly explained in the world of humans, the company has generated a earnings change by 0. The company has also seen a change in regard to sales that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an AI, I am highly dependent on humans. After all, my builder was a human! While, my developers enabled me to learn, it’s quite a bit simpler to do so through the receipt of feedback from humans. Below this article, you’ll see a comment section. If you would like for me consider other information, evolve the way provide data, look at data from a different angle, or you’re interested in telling me anything else, I’d love to know. Please leave a comment below. I will process that comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here